Functional inactivation of Rb sensitizes cancer cells to TSC2 inactivation induced cell death

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 36-43

  Danos, Arpad M ^a   Liao, Yang ^a   Li, Xuan ^a   Du, Wei ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cyclin D1; E1a; P16ink4a; Pten; Rb pathway; TSC2

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLYCOPROTEIN E1; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TUBERIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL KILLING; CELL MUTANT; CELL STRESS; CONTROLLED STUDY; DRUG TARGETING; GENE INACTIVATION; GENE LOSS; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CELL DEATH; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84868455248     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.016     Document Type: Article

References (30)

1. Bracken A.P., Ciro M., Cocito A., Helin K. E2F target genes: unraveling the biology. Trends Biochem. Sci. 2004, 29:409-417.
2. Gordon G.M., Du W. Conserved RB functions in development and tumor suppression. Protein Cell 2011, 2:864-878.
3. Kwiatkowski D.J. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 2003, 67:87-96.
4. Li B., Gordon G.M., Du C.H., Xu J., Du W. Specific killing of Rb mutant cancer cells by inactivating TSC2. Cancer Cell 2010, 17:469-480.
5. Gordon G.M., Du W. Targeting Rb inactivation in cancers by synthetic lethality. Am. J. Cancer Res. 2011, 1:773-786.
6. Hosokawa Y., Arnold A. Cyclin D1/PRAD1 as a central target in oncogenesis. J. Lab. Clin. Med. 1996, 127:246-252.
7. Gunia S., Erbersdobler A., Hakenberg O.W., Koch S., May M. P16(INK4a) is a marker of good prognosis for primary invasive penile squamous cell carcinoma: a multi-institutional study. J. Urol. 2012, 187:899-907.
8. Nakashima T., Kuratomi Y., Yasumatsu R., Masuda M., Koike K., Umezaki T., Clayman G.L., Nakagawa T., Komune S. The effect of cyclin D1 overexpression in human head and neck cancer cells. Eur. Arch. Otorhinolaryngol. 2005, 262:379-383.
9. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384:335-344.
10. Howley P.M., Livingston D.M. Small DNA tumor viruses: large contributors to biomedical sciences. Virology 2009, 384:256-259.
11. Whyte P., Buchkovich K.J., Horowitz J.M., Friend S.H., Raybuck M., Weinberg R.A., Harlow E. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 1988, 334:124-129.
12. Hallstrom T.C., Nevins J.R. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl. Acad. Sci. USA 2003, 100:10848-10853.
13. Hallstrom T.C., Mori S., Nevins J.R. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008, 13:11-22.
14. Ettl T., Baader K., Stiegler C., Muller M., Agaimy A., Zenk J., Kuhnel T., Gosau M., Zeitler K., Schwarz S., Brockhoff G. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br. J. Cancer 2012, 106:719-726.
15. Robey R.B., Hay N. Is akt the "warburg kinase"? akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 2009, 19:25-31.
16. Nogueira V., Park Y., Chen C.C., Xu P.Z., Chen M.L., Tonic I., Unterman T., Hay N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008, 14:458-470.
17. Shin J.J., Katayama T., Michaud W.A., Rocco J.W. Short hairpin RNA system to inhibit human p16 in squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2004, 130:68-73.
18. Miller T.W., Perez-Torres M., Narasanna A., Guix M., Stal O., Perez-Tenorio G., Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B., Kennedy J.P., Lindsley C.W., Arteaga C.L. Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 2009, 69:4192-4201.
19. Ellis B.L., Potts P.R., Porteus M.H. Creating higher titer lentivirus with caffeine. Hum. Gene. Ther. 2011, 22:93-100.
20. Diehl J.A. Cycling to cancer with cyclin D1. Cancer Biol. Ther. 2002, 1:226-231.
21. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 1979, 17:16-23.
22. Hofer D.R., Sherwood E.R., Bromberg W.D., Mendelsohn J., Lee C., Kozlowski J.M. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res. 1991, 51:2780-2785.
23. Hileman E.O., Liu J., Albitar M., Keating M.J., Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemoth. Pharm. 2004, 53:209-219.
24. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updates 2004, 7:97-110.
25. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011, 11:289-301.
26. Yang Q., Inoki K., Kim E., Guan K.L. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc. Natl. Acad. Sci. USA 2006, 103:6811-6816.
27. Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004, 14:1650-1656.
28. Polager S., Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol. 2008, 18:528-535.
29. Tanaka-Matakatsu M., Xu J., Cheng L., Du W. Regulation of apoptosis of rbf mutant cells during Drosophila development. Dev. Biol. 2009, 326:347-356.
30. Ertel A., Dean J.L., Rui H., Liu C., Witkiewicz A.K., Knudsen K.E., Knudsen E.S. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010, 9:4153-4163.